论文部分内容阅读
目的探讨培美曲塞联合奈达铂二线治疗对肺腺癌患者近期疗效及远期生存率的影响。方法将2012年5月-2015年6月延安大学附属医院收治的100例肺腺癌患者随机分为观察组(n=50)和对照组(n=50),观察组采用培美曲塞二钠联合奈达铂治疗,对照组采用多西他赛联合奈达铂治疗,比较两组近期疗效、远期生存期及安全性。结果观察组有效率(RR)为72.0%(36/50),疾病控制率(DCR)为88.0%(44/50),明显高于对照组的44.0%(22/50)、64.0%(32/50),差异有统计学意义(P<0.05);观察组中位无进展生存期(PFS)为10.3个月,中位总生存期(OS)为23.5个月;对照组为7.1个月和16.8个月,差异有统计学意义(P<0.05);观察组1年生存率为52.0%(26/50),对照组为24.0%(12/50),差异有统计学意义(P<0.05);观察组Ⅰ-Ⅳ血小板减少、白细胞降低及脱发发生率均明显低于对照组,差异有统计学意义(P<0.05)。结论培美曲塞联合奈达铂二线治疗肺腺癌近期疗效显著,患者远期生存率高,毒副作用少,值得在临床上推广应用。
Objective To investigate the effect of pemetrexed combined with nedaplatin second-line therapy on short-term and long-term survival of patients with lung adenocarcinoma. Methods 100 patients with lung adenocarcinoma admitted to Yan’an University Affiliated Hospital from May 2012 to June 2015 were randomly divided into observation group (n = 50) and control group (n = 50). The observation group was treated with pemetrexed two Sodium combined nedaplatin treatment, the control group docetaxel combined with nedaplatin treatment, the two groups of short-term efficacy, long-term survival and safety. Results The effective rate (RR) of the observation group was 72.0% (36/50) and the disease control rate (DCR) was 88.0% (44/50), significantly higher than that of the control group (44.0% / 50), the difference was statistically significant (P <0.05); the median progression-free survival (PFS) in the observation group was 10.3 months, the median overall survival (OS) was 23.5 months; the control group was 7.1 months And 16.8 months (P <0.05). The 1-year survival rate was 52.0% (26/50) in the observation group and 24.0% (12/50) in the control group, with significant difference (P < 0.05). The incidence of thrombocytopenia, leukopenia and hair loss in group Ⅰ-Ⅳ in observation group were significantly lower than those in control group (P <0.05). Conclusion Pemetrexed combined with nedaplatin second-line treatment of lung adenocarcinoma has a significant effect in the near future. The long-term survival rate of patients with high toxicity and side effects, it is worth in the clinical application.